Hamamoto Yasushi, Kataoka Masaaki, Senba Takatoshi, Uwatsu Kotaro, Oda Shogo, Takahashi Tadaaki, Aono Shoji, Sakai Shinya, Inoue Takeshi, Sugawara Yoshifumi
Department of Radiology, Shikoku Cancer Center, 160 Kou, Minamiumemoto-machi, Matsuyama, 791-0280, Japan.
Jpn J Radiol. 2009 Jan;27(1):25-30. doi: 10.1007/s11604-008-0292-1. Epub 2009 Feb 8.
The incidence and patterns of isolated brain failure was examined in patients with stage III non-small-cell lung cancer (NSCLC) treated with concurrent chemoradiation (CCRT).
Between 1996 and 2003, a total of 68 patients with stage III NSCLC were treated with radical CCRT. Among them, 63 patients were evaluable. Radiation therapy with a mean total dose of 61.4 Gy and chemotherapy (typically platinum-based) were administered concurrently.
Other than locoregional failure, isolated brain failure was the most common failure pattern as the initial failure, occurring 2-37 months (median 6.5 months) after radical CCRT. The isolated brain failure rates as the initial failure at 1, 3, and 4 years were 9%, 13%, and 25%, respectively. Isolated brain failure as the initial failure occurred more frequently in T4 cases (39% at 4 years) compared to T1-3 cases (14% at 4 years) in our series (P = 0.0099).
Except for locoregional failure, isolated brain failure was the most common initial failure pattern of stage III NSCLCs treated with radical CCRT. Isolated brain failure as the initial failure occurred even after 3 years. Isolated brain failure as the initial failure occurred more frequently in T4 cases than in T1-3 cases.
